Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 a pooled analysis of 1201 population-representative studies with 104 million par...

Autores: Zhou, Bin; Carrillo Larco, Rodrigo M.; Danaei, Goodarz; Riley, Leanne M.; Paciorek, Christopher J.; Stevens, Gretchen A.; Gregg, Edward W.; Bennett, James E.; Solomon, Bethlehem; Singleton, Rosie K.; Sophiea, Marisa K.; Iurilli, Maria LC; Lhoste, Victor PF; Cowan, Melanie J.; Savin, Stefan; Woodward, Mark; Balanova, Yulia; Cifkova, Renata; Damasceno, Albertino; Elliott, Paul; Farzadfar, Farshad; He, Jiang; Ikeda, Nayu; Kengne, Andre P.; Khang, Young Ho; Chang Kim, Hyeon; Laxmaiah, Avula; Lin, Hsien Ho; Margozzini Maira, Paula; Rubinstein, Adolfo Luis
Año de publicación: 2021
Idioma: inglés
Tipo de recurso: artículo
Estado: versión publicada
Descripción: BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO.
Fil: Zhou, Bin. Imperial College London; Reino Unido
Fil: Carrillo Larco, Rodrigo M.. Imperial College London; Reino Unido
Fil: Danaei, Goodarz. Harvard Medical School; Estados Unidos
Fil: Riley, Leanne M.. WHO; Suiza
Fil: Paciorek, Christopher J.. University of California; Estados Unidos
Fil: Stevens, Gretchen A.. Imperial College London; Reino Unido
Fil: Gregg, Edward W.. Imperial College London; Reino Unido
Fil: Bennett, James E.. Imperial College London; Reino Unido
Fil: Solomon, Bethlehem. Imperial College London; Reino Unido
Fil: Singleton, Rosie K.. Imperial College London; Reino Unido
Fil: Sophiea, Marisa K.. Imperial College London; Reino Unido
Fil: Iurilli, Maria LC. Imperial College London; Reino Unido
Fil: Lhoste, Victor PF. Imperial College London; Reino Unido
Fil: Cowan, Melanie J.. WHO; Suiza
Fil: Savin, Stefan. WHO; Suiza
Fil: Woodward, Mark. Imperial College London; Reino Unido. University of New South Wales; Australia
Fil: Balanova, Yulia. National Medical Research Centre for Therapy and Preventive Medicine; Rusia
Fil: Cifkova, Renata. Karlova Univerzita; República Checa
Fil: Damasceno, Albertino. Eduardo Mondlane University; Mozambique
Fil: Elliott, Paul. Imperial College London; Reino Unido
Fil: Farzadfar, Farshad. Non-Communicable Diseases Research Center; Irán
Fil: He, Jiang. University of Tulane; Estados Unidos
Fil: Ikeda, Nayu. National Institutes of Biomedical Innovation, Health and Nutrition; Japón
Fil: Kengne, Andre P.. South African Medical Research Council; Sudáfrica
Fil: Khang, Young Ho. Seoul National University College of Medicine; Corea del Sur
Fil: Chang Kim, Hyeon. Yonsei University College of Medicine; Corea del Sur
Fil: Laxmaiah, Avula. National Institute of Nutrition; India
Fil: Lin, Hsien Ho. National Taiwan University; China
Fil: Margozzini Maira, Paula. Pontificia Universidad Católica de Chile; Chile
Fil: Rubinstein, Adolfo Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Materia: Global Health
Antihypertensive Agents
Hypertension
Prevalence
Nivel de accesibilidad: acceso abierto
Condiciones de uso: https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
Institución: Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador: oai:ri.conicet.gov.ar:11336/212637

Acceder

id	CONICETDig_b692b251be53f6013bf7f0a6c350c654
oai_identifier_str	oai:ri.conicet.gov.ar:11336/212637
network_acronym_str	CONICETDig
repository_id_str	3498
network_name_str	CONICET Digital (CONICET)
spelling	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 a pooled analysis of 1201 population-representative studies with 104 million participantsZhou, BinCarrillo Larco, Rodrigo M.Danaei, GoodarzRiley, Leanne M.Paciorek, Christopher J.Stevens, Gretchen A.Gregg, Edward W.Bennett, James E.Solomon, BethlehemSingleton, Rosie K.Sophiea, Marisa K.Iurilli, Maria LCLhoste, Victor PFCowan, Melanie J.Savin, StefanWoodward, MarkBalanova, YuliaCifkova, RenataDamasceno, AlbertinoElliott, PaulFarzadfar, FarshadHe, JiangIkeda, NayuKengne, Andre P.Khang, Young HoChang Kim, HyeonLaxmaiah, AvulaLin, Hsien HoMargozzini Maira, PaulaRubinstein, Adolfo LuisGlobal HealthAntihypertensive AgentsHypertensionPrevalencehttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO.Fil: Zhou, Bin. Imperial College London; Reino UnidoFil: Carrillo Larco, Rodrigo M.. Imperial College London; Reino UnidoFil: Danaei, Goodarz. Harvard Medical School; Estados UnidosFil: Riley, Leanne M.. WHO; SuizaFil: Paciorek, Christopher J.. University of California; Estados UnidosFil: Stevens, Gretchen A.. Imperial College London; Reino UnidoFil: Gregg, Edward W.. Imperial College London; Reino UnidoFil: Bennett, James E.. Imperial College London; Reino UnidoFil: Solomon, Bethlehem. Imperial College London; Reino UnidoFil: Singleton, Rosie K.. Imperial College London; Reino UnidoFil: Sophiea, Marisa K.. Imperial College London; Reino UnidoFil: Iurilli, Maria LC. Imperial College London; Reino UnidoFil: Lhoste, Victor PF. Imperial College London; Reino UnidoFil: Cowan, Melanie J.. WHO; SuizaFil: Savin, Stefan. WHO; SuizaFil: Woodward, Mark. Imperial College London; Reino Unido. University of New South Wales; AustraliaFil: Balanova, Yulia. National Medical Research Centre for Therapy and Preventive Medicine; RusiaFil: Cifkova, Renata. Karlova Univerzita; República ChecaFil: Damasceno, Albertino. Eduardo Mondlane University; MozambiqueFil: Elliott, Paul. Imperial College London; Reino UnidoFil: Farzadfar, Farshad. Non-Communicable Diseases Research Center; IránFil: He, Jiang. University of Tulane; Estados UnidosFil: Ikeda, Nayu. National Institutes of Biomedical Innovation, Health and Nutrition; JapónFil: Kengne, Andre P.. South African Medical Research Council; SudáfricaFil: Khang, Young Ho. Seoul National University College of Medicine; Corea del SurFil: Chang Kim, Hyeon. Yonsei University College of Medicine; Corea del SurFil: Laxmaiah, Avula. National Institute of Nutrition; IndiaFil: Lin, Hsien Ho. National Taiwan University; ChinaFil: Margozzini Maira, Paula. Pontificia Universidad Católica de Chile; ChileFil: Rubinstein, Adolfo Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; ArgentinaElsevier Science Inc.2021-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/212637Zhou, Bin; Carrillo Larco, Rodrigo M.; Danaei, Goodarz; Riley, Leanne M.; Paciorek, Christopher J.; et al.; Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 a pooled analysis of 1201 population-representative studies with 104 million participants; Elsevier Science Inc.; Lancet; 398; 10304; 9-2021; 957-9800140-6736CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/S0140-6736(21)01330-1info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0140673621013301info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-12-03T09:32:19Zoai:ri.conicet.gov.ar:11336/212637instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-12-03 09:32:19.402CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 a pooled analysis of 1201 population-representative studies with 104 million participants
title	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 a pooled analysis of 1201 population-representative studies with 104 million participants
spellingShingle	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 a pooled analysis of 1201 population-representative studies with 104 million participants Zhou, Bin Global Health Antihypertensive Agents Hypertension Prevalence
title_short	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 a pooled analysis of 1201 population-representative studies with 104 million participants
title_full	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 a pooled analysis of 1201 population-representative studies with 104 million participants
title_fullStr	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 a pooled analysis of 1201 population-representative studies with 104 million participants
title_full_unstemmed	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 a pooled analysis of 1201 population-representative studies with 104 million participants
title_sort	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 a pooled analysis of 1201 population-representative studies with 104 million participants
dc.creator.none.fl_str_mv	Zhou, Bin Carrillo Larco, Rodrigo M. Danaei, Goodarz Riley, Leanne M. Paciorek, Christopher J. Stevens, Gretchen A. Gregg, Edward W. Bennett, James E. Solomon, Bethlehem Singleton, Rosie K. Sophiea, Marisa K. Iurilli, Maria LC Lhoste, Victor PF Cowan, Melanie J. Savin, Stefan Woodward, Mark Balanova, Yulia Cifkova, Renata Damasceno, Albertino Elliott, Paul Farzadfar, Farshad He, Jiang Ikeda, Nayu Kengne, Andre P. Khang, Young Ho Chang Kim, Hyeon Laxmaiah, Avula Lin, Hsien Ho Margozzini Maira, Paula Rubinstein, Adolfo Luis
author	Zhou, Bin
author_facet	Zhou, Bin Carrillo Larco, Rodrigo M. Danaei, Goodarz Riley, Leanne M. Paciorek, Christopher J. Stevens, Gretchen A. Gregg, Edward W. Bennett, James E. Solomon, Bethlehem Singleton, Rosie K. Sophiea, Marisa K. Iurilli, Maria LC Lhoste, Victor PF Cowan, Melanie J. Savin, Stefan Woodward, Mark Balanova, Yulia Cifkova, Renata Damasceno, Albertino Elliott, Paul Farzadfar, Farshad He, Jiang Ikeda, Nayu Kengne, Andre P. Khang, Young Ho Chang Kim, Hyeon Laxmaiah, Avula Lin, Hsien Ho Margozzini Maira, Paula Rubinstein, Adolfo Luis
author_role	author
author2	Carrillo Larco, Rodrigo M. Danaei, Goodarz Riley, Leanne M. Paciorek, Christopher J. Stevens, Gretchen A. Gregg, Edward W. Bennett, James E. Solomon, Bethlehem Singleton, Rosie K. Sophiea, Marisa K. Iurilli, Maria LC Lhoste, Victor PF Cowan, Melanie J. Savin, Stefan Woodward, Mark Balanova, Yulia Cifkova, Renata Damasceno, Albertino Elliott, Paul Farzadfar, Farshad He, Jiang Ikeda, Nayu Kengne, Andre P. Khang, Young Ho Chang Kim, Hyeon Laxmaiah, Avula Lin, Hsien Ho Margozzini Maira, Paula Rubinstein, Adolfo Luis
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	Global Health Antihypertensive Agents Hypertension Prevalence
topic	Global Health Antihypertensive Agents Hypertension Prevalence
purl_subject.fl_str_mv	https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv	BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO. Fil: Zhou, Bin. Imperial College London; Reino Unido Fil: Carrillo Larco, Rodrigo M.. Imperial College London; Reino Unido Fil: Danaei, Goodarz. Harvard Medical School; Estados Unidos Fil: Riley, Leanne M.. WHO; Suiza Fil: Paciorek, Christopher J.. University of California; Estados Unidos Fil: Stevens, Gretchen A.. Imperial College London; Reino Unido Fil: Gregg, Edward W.. Imperial College London; Reino Unido Fil: Bennett, James E.. Imperial College London; Reino Unido Fil: Solomon, Bethlehem. Imperial College London; Reino Unido Fil: Singleton, Rosie K.. Imperial College London; Reino Unido Fil: Sophiea, Marisa K.. Imperial College London; Reino Unido Fil: Iurilli, Maria LC. Imperial College London; Reino Unido Fil: Lhoste, Victor PF. Imperial College London; Reino Unido Fil: Cowan, Melanie J.. WHO; Suiza Fil: Savin, Stefan. WHO; Suiza Fil: Woodward, Mark. Imperial College London; Reino Unido. University of New South Wales; Australia Fil: Balanova, Yulia. National Medical Research Centre for Therapy and Preventive Medicine; Rusia Fil: Cifkova, Renata. Karlova Univerzita; República Checa Fil: Damasceno, Albertino. Eduardo Mondlane University; Mozambique Fil: Elliott, Paul. Imperial College London; Reino Unido Fil: Farzadfar, Farshad. Non-Communicable Diseases Research Center; Irán Fil: He, Jiang. University of Tulane; Estados Unidos Fil: Ikeda, Nayu. National Institutes of Biomedical Innovation, Health and Nutrition; Japón Fil: Kengne, Andre P.. South African Medical Research Council; Sudáfrica Fil: Khang, Young Ho. Seoul National University College of Medicine; Corea del Sur Fil: Chang Kim, Hyeon. Yonsei University College of Medicine; Corea del Sur Fil: Laxmaiah, Avula. National Institute of Nutrition; India Fil: Lin, Hsien Ho. National Taiwan University; China Fil: Margozzini Maira, Paula. Pontificia Universidad Católica de Chile; Chile Fil: Rubinstein, Adolfo Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
description	BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO.
publishDate	2021
dc.date.none.fl_str_mv	2021-09
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	http://hdl.handle.net/11336/212637 Zhou, Bin; Carrillo Larco, Rodrigo M.; Danaei, Goodarz; Riley, Leanne M.; Paciorek, Christopher J.; et al.; Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 a pooled analysis of 1201 population-representative studies with 104 million participants; Elsevier Science Inc.; Lancet; 398; 10304; 9-2021; 957-980 0140-6736 CONICET Digital CONICET
url	http://hdl.handle.net/11336/212637
identifier_str_mv	Zhou, Bin; Carrillo Larco, Rodrigo M.; Danaei, Goodarz; Riley, Leanne M.; Paciorek, Christopher J.; et al.; Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 a pooled analysis of 1201 population-representative studies with 104 million participants; Elsevier Science Inc.; Lancet; 398; 10304; 9-2021; 957-980 0140-6736 CONICET Digital CONICET
dc.language.none.fl_str_mv	eng
language	eng
dc.relation.none.fl_str_mv	info:eu-repo/semantics/altIdentifier/doi/10.1016/S0140-6736(21)01330-1 info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0140673621013301
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv	openAccess
rights_invalid_str_mv	https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv	application/pdf application/pdf
dc.publisher.none.fl_str_mv	Elsevier Science Inc.
publisher.none.fl_str_mv	Elsevier Science Inc.
dc.source.none.fl_str_mv	reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str	CONICET Digital (CONICET)
collection	CONICET Digital (CONICET)
instname_str	Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv	CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv	dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_	1850505706121199616
score	13.214268

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 a pooled analysis of 1201 population-representative studies with 104 million par...

Publicaciones similares